A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) (GX-03 in AD)

A Double-Blind, Vehicle-Controlled Study to Assess the Efficacy of GX-03 When Used in a Population of Adult Individuals With Moderate to Severe Eczema

This is a Phase 2, randomized, double-blind, vehicle-controlled clinical study evaluating the efficacy and safety of GX-03 topical ointment in adult subjects with moderate to severe atopic dermatitis (eczema). The study plans to enroll up to 120 eligible patients with a target of at least 100 completing the study and an ability to expand enrollment up to 200 subjects based on a pre-specified interim assessment conducted by an Independent Data Monitoring Committee (IDMC). Subjects will be randomized in a 1:1 ratio to receive either GX-03 or vehicle control for 8 weeks.

The study is designed to evaluate improvement in investigator-assessed disease severity, itch, and patient-reported eczema symptoms following topical treatment with GX-03 compared with vehicle control. Efficacy assessments include the Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™), Eczema Area and Severity Index (EASI), Peak Pruritus Numeric Rating Scale (PP-NRS), and Patient-Oriented Eczema Measure (POEM).

An interim assessment of conditional power for the primary efficacy endpoint will occur after the first 50 subjects complete the Week 8 visit or withdraw prematurely. Based on pre-specified criteria defined in the IDMC Charter, the IDMC may recommend continuation as planned, expansion of enrollment up to 200 subjects, or early curtailment of enrollment.

Study Overview

• Status: Recruiting
• Conditions: Eczema; Atopic Dermatitis; Eczema Atopic Dermatitis
• Intervention / Treatment: Other: Vehicle; Combination product: GX-03

Detailed Description

This Phase 2 study is designed to evaluate the efficacy and safety of GX-03, a topical petrolatum-based ointment containing polyhexanide (PHMB), in adult subjects with moderate to severe atopic dermatitis.

The study plans to enroll up to 120 eligible patients with a target of at least 100 completing the study and an ability to expand enrollment up to 200 subjects based on a pre-specified interim assessment conducted by an Independent Data Monitoring Committee (IDMC). Eligible subjects will be randomized in a double-blind manner to receive either GX-03 or matching vehicle control in a 1:1 allocation ratio. Study treatment will be self-administered topically to affected areas at least twice daily for 8 consecutive weeks.

Subjects will undergo efficacy evaluations at Baseline, Week 4, and Week 8 using validated atopic dermatitis assessment tools including vIGA-AD™, EASI, PP-NRS, and POEM. Safety assessments will include adverse event monitoring, concomitant medication review, and weekly safety check-ins.

The study incorporates an adaptive design with a single unblinded interim assessment performed by an independent IDMC after approximately 50 evaluable subjects have completed the Week 8 assessment or withdrawn prematurely. The interim analysis will evaluate conditional power for the primary endpoint and may result in continuation without modification, expansion of enrollment up to 200 total subjects, or curtailment of enrollment according to pre-specified criteria.

Statistical Analysis:

The primary efficacy analysis will compare treatment groups using a one-sided superiority hypothesis with a significance level of 0.025. Multiplicity across endpoints will be controlled using a hierarchical stepdown testing procedure. Safety analyses will be performed using two-sided statistical testing.

The Full Analysis Set (FAS) will serve as the primary efficacy population and includes randomized subjects who received at least one dose of study treatment and completed the Week 8 post-baseline EASI assessment.

Interim Analysis A single unblinded interim assessment will be conducted by an Independent Data Monitoring Committee after approximately 50 subjects complete the Week 8 visit or withdraw prematurely. The interim assessment will evaluate conditional power for the primary endpoint and may support continuation as planned, enrollment expansion up to 200 subjects, or curtailment of enrollment based on pre-specified IDMC criteria.

Safety Monitoring Safety evaluations include treatment-emergent adverse events, serious adverse events, concomitant medications, and weekly safety monitoring throughout the study duration.

• Study Type: Interventional
• Enrollment (Estimated): 110
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Barry Reece, MS; Phone Number: 9728714371; Email: barry.reece@alsglobal.com

Study Locations

• United States
  • Texas
    • Irving, Texas, United States, 75062
      • Recruiting
      • ALS Global
      • Contact: Jordan Williams; Phone Number: 9725732908; Email: jordan.williams@alsglobal.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Participants must meet all of the following criteria:

• Adults aged 18 to 80 years, inclusive
• Male or female subjects in good general health as determined by medical history
• Presence of visible eczematous skin with disease severity consistent with moderate to severe eczema, as assessed by:
• Eczema Area and Severity Index (EASI) or Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™)
• Ability to read, understand, and provide written informed consent in English
• Willingness and ability to comply with study procedures, including study visits and daily topical application
• Agreement to use only the assigned study product on designated areas of interest for the duration of the study

Exclusion Criteria

Individuals meeting any of the following criteria will be excluded:

• Pregnant, breastfeeding, or planning pregnancy during the study
• Presence of any skin condition or dermatologic disease that could interfere with study treatment or assessments
• Use of systemic or topical immunosuppressive therapies, including corticosteroids, within 3 weeks prior to enrollment
• Use of anti-inflammatory medications (e.g., topical steroids, ibuprofen, celecoxib); steroid nasal or ophthalmic drops are permitted
• Use of topical medications at the test sites within 72 hours prior to enrollment
• Damaged or altered skin at or near test sites (e.g., sunburn, tattoos, scars, uneven pigmentation) that could confound evaluations
• Any medical condition that, in the investigator's judgment, places the subject at undue risk or compromises study integrity

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: GX-03; Treatment Arm	Combination product: GX-03; Topical ointment
Experimental: Vehicle; Vehicle Control	Other: Vehicle; Ointment carrier

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Investigator Global Assessment (IGA) at Week 8	vIGA-AD score of 0 (clear) or 1 (almost clear) with a ≥2-grade improvement from baseline at Week 8	At Day 56 (Week 8)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Baseline Eczema Area and Severity (EASI) at Week 8	Change in EASI from Baseline to week 8	At Day 56 (Week 8)
≥4 Point reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) at Week 8	≥4 Point reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) from baseline to week 8	At Day 56 (Week 8)
Patient-Oriented Eczema Measure (POEM) score at Week 8	Patient-Oriented Eczema Measure (POEM) questionnaire response at week 8	At Day 56 (Week 8)

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline in Validated Investigator Global Assessment (vIGA-AD) at Week 4	vIGA-AD score of 0 (clear) or 1 (almost clear) with a ≥2-grade improvement from baseline at Week 4	At Day 28 (Week 4)
Change from Baseline in Eczema Area Severity Index (EASI) at Week 4	Change from Baseline in Eczema Area Severity Index (EASI) at Week 4	At Day 28 (Week 4)
≥4 Point reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) at Week 4	≥4 Point reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) from baseline to week 4	At Day 28 (Week 4)
Patient-Oriented Eczema Measure (POEM) score at Week 4	Patient-Oriented Eczema Measure (POEM) questionnaire response at Week 4	At Day 28 (Week 4)
Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)	Incidence, nature, severity, and causal relationship of treatment-emergent adverse events (TEAEs) from time of first application through the final visit.	Up to 8 Weeks (Treatment Period)

Collaborators and Investigators

• Sponsor: Turn Therapeutics

Publications and helpful links

Helpful Links

• Sponsor Website

Study record dates

Study Major Dates

• Study Start (Actual): July 11, 2025
• Primary Completion (Estimated): July 10, 2026
• Study Completion (Estimated): July 10, 2026

Study Registration Dates

• First Submitted: January 19, 2026
• First Submitted That Met QC Criteria: January 20, 2026
• First Posted (Actual): January 21, 2026

Study Record Updates

• Last Update Posted (Actual): May 18, 2026
• Last Update Submitted That Met QC Criteria: May 13, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: Atopic Dermatitis; Eczema; Moderate-Severe AD; Moderate-Severe Eczema
• Additional Relevant MeSH Terms: Genetic Diseases, Inborn; Immune System Diseases; Hypersensitivity, Immediate; Hypersensitivity; Skin Diseases; Skin Diseases, Genetic; Skin Diseases, Eczematous; Dermatitis; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin and Connective Tissue Diseases; Dermatitis, Atopic; Eczema
• Other Study ID Numbers: Protocol/Panel 4604

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Protection of participant privacy and re-identification risks Ongoing regulatory or commercial activities Intellectual property and competitive concerns Resource and practical barriers

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No